25 August 2016Big Pharma

Video interview: Hogan Lovells discusses implications of Brexit on SPCs

In an exclusive interview with LSIPR, Stephen Bennett, partner at Hogan Lovells, talks about the implications of Brexit with a focus on supplementary protection certificates (SPCs).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

A clearer picture for SPCs?

8 October 2015 The CJEU’s decision on how an SPC term is to be determined is likely to be welcomed by applicants and owners, but the court has left them to work out how to apply the ruling, say Natalia Wegner-Cribbs and Daniel Wise of Carpmaels & Ransford.

Biotechnology

CJEU adviser to give opinion on SPC term

9 September 2015 An adviser at Europe’s highest court is expected to issue an opinion on whether the term of a supplementary protection certificate begins once it is authorised or when the applicant has been notified about it.

More on this story

A clearer picture for SPCs?

8 October 2015 The CJEU’s decision on how an SPC term is to be determined is likely to be welcomed by applicants and owners, but the court has left them to work out how to apply the ruling, say Natalia Wegner-Cribbs and Daniel Wise of Carpmaels & Ransford.

Biotechnology

CJEU adviser to give opinion on SPC term

9 September 2015 An adviser at Europe’s highest court is expected to issue an opinion on whether the term of a supplementary protection certificate begins once it is authorised or when the applicant has been notified about it.

More on this story

A clearer picture for SPCs?

8 October 2015 The CJEU’s decision on how an SPC term is to be determined is likely to be welcomed by applicants and owners, but the court has left them to work out how to apply the ruling, say Natalia Wegner-Cribbs and Daniel Wise of Carpmaels & Ransford.

Biotechnology

CJEU adviser to give opinion on SPC term

9 September 2015 An adviser at Europe’s highest court is expected to issue an opinion on whether the term of a supplementary protection certificate begins once it is authorised or when the applicant has been notified about it.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent